Pulmicort Respules Budesonide Suspension

Pulmicort Budesonide Respules Features

• Pulmicort Respules can help improve your child's asthma symptoms
• Helps reduce swelling and inflammation in the lungs and helps keep the airways open to reduce asthma symptoms
• By breathing through a jet nebulizer, your child receives the medicine in his or her lungs
• When an envelope has been opened, the shelf life of the unused RESPULES ampules is 2 weeks when protected
• Available in a once-daily dosing option or, if not adequately effective, as a twice-daily dosing option

What to buy with Budesonide Oral Inhalation

• AIRFREE IRIS 3000 Filterless Air Purifier
• Bluechip Hospital Patient Allergy Proof Pillow

How to take Pulmicort Respules Budesonide Oral Inhalation?

Recommended dosing based on previous therapy (2). Start with the lowest recommended dose:

• Bronchodilators alone: 0.5 mg once daily or 0.25 mg twice daily
• Inhaled corticosteroids: 0.5 mg once daily or 0.25 mg twice daily up to 0.5 mg twice daily
• Oral corticosteroids: 0.5 mg twice daily or 1 mg once daily
• In symptomatic children not responding to non-steroidal therapy, a starting dose of 0.25 mg once daily may be considered
• If once-daily treatment does not provide adequate control, the total daily dose should be increased and administered as a divided dose. Once asthma stability is achieved, titrate the dose downwards
• For inhalation use via compressed air-driven jet nebulizers only (not for use with ultrasonic devices). Not for injection. (2.2)

Important Safety Information:

• Pulmicort Respules is not a bronchodilator and should not be used to treat an acute asthma attack. If your child is switching to PULMICORT RESPULES from an oral corticosteroid, follow the doctor's instructions to avoid serious health risks when your child stops using oral corticosteroids.
• Only use Pulmicort Respules with a jet nebulizer machine that is connected to an air compressor. Do not use an ultrasonic nebulizer.
• Thrush infection of the mouth and throat may occur with Pulmicort Respules.
• Avoid exposure of your child to infections such as chicken pox and measles. Tell your doctor immediately if your child is exposed.
• Inhaled corticosteroids may cause a reduction in growth rate. The long-term effect on final adult height is unknown.
• Pulmicort Respules should not be used if your child is allergic to budesonide or any of the ingredients.
• Be sure to tell the healthcare provider about all your child's health conditions and all medicines he or she may be taking.
• As with other inhaled asthma medications, bronchospasm, with an immediate increase in wheezing, may occur after dosing. If bronchospasm occurs following dosing with Pulmicort Respules, it should be treated immediately with a fast-acting inhaled bronchodilator. Treatment with Pulmicort Respules should be stopped, and your physician should be consulted.
• The most common side effects include respiratory infection, runny nose, coughing, ear infection, viral infection, thrush in the mouth and throat, inflammation of the stomach including vomiting, diarrhea, abdominal pain and loss of appetite, nose bleed, pink eye, and rash.

Warnings and Precautions:

• Localized Infections: Candida albicans infection of the mouth and throat may occur. Monitor patients periodically for signs of adverse effects on the oral cavity. Advise patients to rinse the mouth following inhalation.
• Deterioration of Disease and Acute Asthma Episodes: Do not use for the relief of acute bronchospasm
• Hypersensitivity Reactions: Anaphylaxis, rash, contact dermatitis, urticaria, angioedema, and bronchospasm have been reported using Pulmicort Respules. Discontinue Pulmicort Respules if such reactions occur.
• Immunosuppression: Potential worsening of infections (e.g., existing tuberculosis, fungal, bacterial, viral, or parasitic infection; or ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal courses of chickenpox or measles can occur in susceptible patients.
• Transferring Patients from Systemic Corticosteroid Therapy: Risk of impaired adrenal function when transferring from oral steroids. Taper patients slowly from systemic corticosteroids if transferring to Pulmicort Respules.
• Hypercorticism and Adrenal Suppression: This may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, reduce Pulmicort Respules slowly.
• Reduction in Bone Mineral Density with Long-term Administration: Monitor patients with major risk factors for decreased bone mineral content.
• Effects on Growth: Monitor the growth of pediatric patients.
• Glaucoma and Cataracts: Close monitoring is warranted.
• Paradoxical Bronchospasm: Discontinue Pulmicort Respules and institute alternative therapy if paradoxical bronchospasm occurs.
• Eosinophilic Conditions and Churg-Strauss Syndrome: Be alert to eosinophilic conditions.